0
Abstract: Poster Presentations |

PROSPECTIVE APPLICATION OF A CLINICAL GUIDELINE TO DIAGNOSE AND TREAT VENTILATOR ASSOCIATED PNEUMONIA IN TRAUMA PATIENTS IMPROVES OUTCOMES FREE TO VIEW

Scott Newbrough, MD*; Nikki Freeman, PharmD; Brian J. Daley, MD; Dana Taylor, MD; Ed Varnadoe, PharmD
Author and Funding Information

UTMCK, Knoxville, TN


Chest


Chest. 2005;128(4_MeetingAbstracts):295S-b-296S. doi:10.1378/chest.128.4_MeetingAbstracts.295S-b
Text Size: A A A
Published online

Abstract

PURPOSE:  Determine if a clinical guideline increased the initial administration of appropriate empiric anti-microbial treatment to trauma patients with ventilator associated pneumonia (VAP). Secondary objectives evaluated duration of mechanical ventilation, ICU and hospital lengths of stay (LOS), drug cost of VAP treatment, and development of super-infection.

METHODS:  A VAP guideline for diagnosis and treatment was developed with the guidelines of the American College of Chest Physicians and the institution’s antibiogram. Once VAP was diagnosed, cultures were obtained and intravenous antibiotics were started within twelve hours - vancomycin 15 mg/kg (renal ajusted dosing), ciprofloxacin 400 mg every eight hours, and piperacillin/tazobactam 4.5 grams every six hours. Once culture and susceptibilities were received, treatment was modified, and limited to seven days. Prospectively enrolled patients were compared to a retrospective cohort before the guideline. Super infection was defined as developing an infection with Serratia, Pseudomonas, Acinetobacter, Citrobacter, Enterobacter, or MRSA.T-test and Chi squared analysis had significance assigned at p< 0.05.

RESULTS:  Forty-nine trauma patients comprise this study; 36 retrospective (12/2002 through 7/2003) and 13 prospective (12/2003 through 12/2004). Before the guideline only 1/36 (2.8%) received appropriate initial antibiotics; after implementation 4/13 patients (30.8%) received appropriate initial antibiotics at maximal doses, a significant improvement. Prospective patients had shoter duration of ventilation and ICU LOS just missing statitiscal validity and hospital lengths of stay were statistically lower in the prospective study group. The mean cost of VAP antibiotic treatment per patient for the retrospective group was significantly higher than the prospective group. Super-infection developed in 29/36 patients (80.6%) in the retrospective group, 8/13 patients (61.5%) developed a super-infection in the prospective group, a decrease which just missed statistical significance.

CONCLUSION:  The guideline diagnosed VAP more carefully decreasing unnecessary antibiotics and ultimately cost of treatment. It also increased appropriate intial treatment and decreased length of hospital stay, time on mechanical ventilation and super infections.

CLINICAL IMPLICATIONS:  Precisely defining diagnosis, evidence based treatment plans and reduced therapeutic variation improved outcome in complex trauma ICU patients.

DISCLOSURE:  Scott Newbrough, None.

Wednesday, November 2, 2005

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543